Our group is focused on discovering small molecule inhibitors of kinases, proteases, and GPCRs that will be optimized for drug development in the areas of neurodegeneration, inflammation, cardiovascular disease, and oncology. We utilize molecular biology, enzymology, receptor pharmacology, structure-based drug design, and in vivo pharmacology to discover potential drug leads, optimize these leads to preclinical candidacy, and further develop these compounds so that an IND can be submitted to the FDA for testing in humans.